AmCham EU provided a response to the open consultation of the BECA (Beating Cancer) Committee of the European Parliament. The consultation addresses the impact of the COVID-19 health crisis on cancer care services and patients. Focusing on both the short- and long-term impacts of COVID-19 the consultation looks at: provision and continuity of care during the pandemic for cancer treatment and screening; lifestyle; the impact on patients and care providers; and related matters on data, research and innovation to improve cancer treatment and healthcare systems in the future. Read our consultation here.
Impact of COVID-19 on cancer care and research
AmCham EU provided a response to the open consultation of the BECA (Beating Cancer) Committee of the European Parliament. The consultation addresses the impact of the COVID-19 health crisis on cancer care services and patients. Focusing on both the short- and long-term impacts of COVID-19 the consultation looks at: provision and continuity of care during the pandemic for cancer treatment and screening; lifestyle; the impact on patients and care providers; and related matters on data, research and innovation to improve cancer treatment and healthcare systems in the future. Read our consultation here.
AmCham EU has highlighted the need for: investment in holistic healthcare systems which support both patients and care givers and have the resilience to guarantee continuity of care even when faced with a pandemic; modernised healthcare infrastructure which is fit for digitalisation and in particular the need to accelerate the standardisation of electronic health records and the electronic patient dossier for efficiency reasons; policies which support healthy lifestyles; and investment in next generation medical devices and manufacturing processes to provide access to innovative treatments to Europe citizens in the future, including the suggestion of a new mission as part of Horizon Europe focused exclusively on health systems innovation.
Related items
:focal())
News
27 Oct 2025
Advancing EU health policy through competitiveness and innovation
On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda.
:focal())
News
9 Oct 2025
Advancing European healthcare in Strasbourg
From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation.
News
4 May 2025
How the Critical Medicines Act will strengthen Europe’s life sciences sector
On Wednesday, 30 April, Thibaut L'Ortye, Senior Director of Public Affairs, AmCham EU, joined a panel discussion on the Critical Medicines Act (CMA). Hosted by the European Policy Centre, Mr L'Ortye underlined the need for open and resilient supply chains to ensure continued access to medicines. He also highlighted the CMA’s potential to strengthen Europe's competitiveness and improve patient access. Avoiding protectionist measures and aligning the CMA with the EU’s wider simplification efforts is essential to attract investment into the Single Market. The discussion highlighted the importance of public-private collaboration to build a more competitive life sciences sector in the EU.
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.